SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: October 16, 2003
QLT Inc.
--------
(Exact name of registrant as specified in its Charter)
British Columbia, Canada 000-17082 N/A
- ------------------------ --------- -------------------
(Jurisdiction of (Commission File Number) (IRS Employer
Incorporation) Identification No.)
QLT Inc.,
887 Great Northern Way,
Vancouver, B.C., CANADA, V5T 4T5
(604) 707-7000
----------------------------
(Address, including zip code, and telephone number,
including area code, of principal executive offices)
ITEM 5. OTHER EVENTS
QLT announced that health authorities in Japan approved Visudyne(R)
(verteporfin) for the treatment of the "wet" form of age-related macular
degeneration (AMD). Specifically, Visudyne has been approved for the orphan
indication of AMD with all types of subfoveal choroidal neovascularization.
ITEM 7. EXHIBITS
Exhibit
Number Description
- ------ -----------
99.1 Press Release dated October 16, 2003
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
QLT Inc.
--------------------------------
(Registrant)
Date October 16, 2003 /s/ Paul J. Hastings
---------------- -------------------------------------
(Signature)
President and Chief Executive Officer